JERUSALEM, July 1 (Reuters) - Teva Pharmaceutical
Industries said on Monday it believes its patents were
properly listed, following a report in the Washington Post that
U.S. regulators had opened a patent investigation into the
Israel-based company.
"Teva believes that its patents are properly listed in the
Orange Book and continues to stand behind the company's
intellectual property," it said in a statement to Reuters.